台鐵車站情報站
台灣鐵路發展超過百年，有完整的環島路線，每個車站都成為當地發展的重要指標，火車站周圍有什麼特別的，看看網紅們怎麼說

Search

關於 progression free survival ，我們在網路上蒐集到這些相關的討論、資訊與評價

相關標籤 相關照片 相關影片
在progression free survival這個產品中，有4篇Facebook貼文，粉絲數超過7萬的網紅加護病房查房日誌，也在其Facebook貼文中提到， 加護病房查房日誌20201020 今天我們來看看Pembrolizumab這個Anti-PD-1 Monoclonal Antibody，和第一線的化療藥品，用於for mismatch repair-deficient metastatic colorectal cancer病人的效果吧。 大約有...

progression free survival 在 加護病房查房日誌 Facebook 的最讚貼文

加護病房查房日誌 By 加護病房查房日誌

2020-10-20 11:29:36 有 120 人按讚
  • Share this:

加護病房查房日誌20201020
今天我們來看看Pembrolizumab這個Anti-PD-1 Monoclonal Antibody，和第一線的化療藥品，用於for mismatch repair-deficient metastatic colorectal cancer病人的效果吧。
大約有3-6%的metastatic colorectal cancers (mCRCs)病人在DNA mismatch repair (dMMR)是缺乏的。這類的病人在初始系統性化療失敗後，對於immune checkpoint inhibitor immunotherapy可能有潛在的好處。
在KEYNOTE-177 trial中初步結果建議使用Pembrolizumab作為第一線的治療，比起原先第一線的化療藥品有更好的效果。對於 progression-free survival 有兩倍，甚至更高的durable objective response rates，也有較少的嚴重不良反應。
文獻來源: Andre T, Shiu K-K, Kim T-W, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study (abstract). J Clin Oncol 38: 2020 (suppl; abstr LBA4). Abstract available online at https://meetinglibrary.asco.org/record/186928/abstract (Accessed on June 10, 2020).

但是目前overall survival data還沒有被發表，基於目前的證據，uptodate的學者建議對於 nonoperable dMMR mCRC 的病人，第一線使用pembrolizumab單一治療比化學治療來的好。在今年六月美國Food and Drug Administration (FDA) 也核准了pembrolizumab用於第一線治療patients with unresectable or metastatic dMMR CRC.。
只是在台灣目前這樣的適應症尚未通過，目前在台灣可用於1.黑色素細胞瘤，2.非小細胞肺癌，3.典型何杰金氏淋巴瘤，4.頭頸部鱗狀細胞癌，5.泌尿道上皮癌，6. 胃癌。

Tags:
加護病房查房日誌

About author
這是一個分享加護病房中查房心得，醫藥新知的地方。以簡單的方式呈現給大家，希望對大家有所幫助。
72845 followers 71038 likes
View all posts

progression free survival 在 เกมถูกบอกด้วย v.2 Facebook 的最佳解答

เกมถูกบอกด้วย v.2 By เกมถูกบอกด้วย v.2

2020-08-28 14:17:05 有 2,462 人按讚
  • Share this:


[News] Spellbreak เกม Battle Royale สอดประสานร่ายเวทพิฆาตศัตรู เตรียมเปิดให้เล่นฟรี ในวันที่ 3 ก.ย. นี้ บน PS4, XB1, Switch และ PC พร้อมระบบการเล่นข้ามแพลตฟอร์ม
.
Proletariat Inc. ได้ประกาศว่า Spellbreak เกมแนว Battle Royale RPG ที่คุณจะได้ร่ายและสอดประสานเวทมนตร์ ในการสร้างกลยุทธ์เพื่อการเอาตัวรอด เตรียมที่จะเปิดให้บริการเป็นเกม Free-to-Play บน PS4, XB1, Switch และ PC ผ่านทาง Epic Games Store ในวันที่ 3 ก.ย. นี้ โดยตัวเกมจะรองรับระบบ Cross-play, Cross-party และ Cross-progression ตั้งแต่วันแรกที่เปิดให้บริการ
.
https://www.youtube.com/watch?v=pSmvbSFUDf8
Spellbreak Official Launch Cinematic Trailer
-------------------------------
แค่เติมเงินก็ได้ Steam Wallet แล้ว >> GetSteamWallet.com
-------------------------------
Humble Choice ประจำเดือน ส.ค. จ่าย $5 ประมาณ 160 บาท (สำหรับสมาชิกใหม่เท่านั้น) รับสตีมคีย์ Vampyr, Hello Neighbor, Wargroove, Call of Cthulhu, The Coma 2, Automachef และอื่นๆ ดูที่นี่ - https://bit.ly/2EAvomy
[News] Spellbreak. Battle Royale game. Coordinated deadly weights. Enemies are prepared to open for free play on 3 July. Oh, my God. This on PS4, XB1, Switch and PC with cross platform system
.
Proletariat Inc. Spellbreak, the Battle Royale RPG game you'll cast and collaborate with magic in creating survival strategies. Prepare to be open for free-to-play games on PS4, XB1, Switch and PC via Epic Games Store on 3 A. K. Oh, my God. This game will support Cross-play, Cross-party and Cross-progression from the first day we open.
.
https://www.youtube.com/watch?v=pSmvbSFUDf8
Spellbreak Official Launch Cinematic Trailer
-------------------------------
Just top up and get Steam Wallet >> GetSteamWallet.com
-------------------------------
Humble Choice of the month. July. Pay $ 5 Approximate 160 Baht (for new members only) Get Vampyr, Hello Neighbour, Wargroove, Call of Cthulhu, The Coma 2, Automachef and more. See here-https://bit.ly/2EAvomyTranslated

Tags:
เกมถูกบอกด้วย v.2

About author
ไม่มีอะไรยอดเยี่ยมเท่าการได้เล่นเกมดีในราคาไม่แพง
523898 followers 503882 likes "http://sheapgamer.com/"
View all posts

progression free survival 在 台灣光鹽生物科技學苑 Facebook 的精選貼文

台灣光鹽生物科技學苑 By 台灣光鹽生物科技學苑

2018-07-12 12:00:01 有 57 人按讚
  • Share this:


<產業訊息>創天價！智擎胰臟癌新藥安能得 獲台灣健保給付價2.64萬元

#健保藥價 #胰臟癌 #臨床試驗 #新藥 #癌症治療指引

智擎（4162）今日宣佈，旗下癌新藥安能得R（ONIVYDER）獲台灣健保局給付

核定藥價，每劑2.64萬元，創下國人研發新藥健保新天價！該新藥給付自今年8月1日起生效。安能得併用 5-FU/LV 療法為目前唯一被法規單位核准適用於曾接受標準藥物 gemcitabine失敗後之轉移性胰腺癌病患的治療，納入健保給付後將正式於台灣地區全面銷售，提供國內胰腺癌病患多一項治療選擇。

本次安能得納入健保給付的評估依據主要為安能得全球第三期臨床試驗（NAPOLI-1），結果顯示接受過標準藥物gemcitabine療法失敗的胰腺癌病人，以安能得併用5-FU/LV療法治療後，相較於僅以5-FU/LV療法治療的病人，其整體存活期（overall survival）、疾病無惡化存活期（progression-free survival）與腫瘤反應率（overall response rate）在臨床統計學上，皆有顯著提高的效果，且不降低病患的生活品質。安能得已被歐洲癌症治療指引（ESMO Clinical Practice Guidelines, 2015）與美國國家癌症指引（NCCN Clinical Practice Guidelines, 2016）列為該病患群的標準療法。

智擎總經理暨執行長葉常菁博士表示:非常感謝健保署及決議過程中專家學者們的支持，使去年7月申請健保藥價核定的安能得順利納入健保給付，且取得合理的核定價格，除了能讓更多需要的胰腺癌病患受惠，同時也是對國內專注創新研發的新藥公司一種實質的鼓勵。

根據衛生福利部國民健康署之統計資料顯示，2015年台灣地區診斷為胰臟癌者共計2,237人，當年度死於胰臟癌者達1,948人，高居台灣癌症死亡原因之第8位。轉移性胰臟癌是一種高度惡性的疾病，致死率很高，通常治療的目標只是控制疾病惡化及延長有限的存活期。

全文網址：http://www.chinatimes.com/realtimenews/20180711003097-260410

2018年07月11日 17:47 工商 杜蕙蓉

Tags:
台灣光鹽生物科技學苑

About author
這個學苑,不僅有生技製藥產業職場從業人員實務培訓課程, 也有最能思考激盪的學習氛圍,還有認真堅持的學員!
這個學苑,不僅有生技製藥產業職場從業人員實務培訓課程, 也有最能思考激盪的學習氛圍,還有認真堅持的學員!
7682 followers 6955 likes "http://www.biotech-edu.com/"
View all posts
社群媒體上有些相關的討論：

progression free survival 在 What are Progression Free Survival (PFS) and Overall ... 的美食出口停車場

影片讀取中

HealthTree University, provided by the Myeloma Crowd, offers a comprehensive online multiple myeloma curriculum with lessons, quizzes and ... ... <看更多>

你可能也想看看
progression-free survival中文
Progression-free survival vs overall survival
Progression-free survival definition
Progression free survival endpoint
Disease-free interval
progression free interval中文
Time to progression and progression-free survival
Invasive disease-free survival
搜尋相關連結

#1. Definition of progression-free survival - NCI Dictionary of ...

progression -free survival ... The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does ...

#2. 以無惡化存活時間(PFS)評估抗癌藥物療效之考量

以「無惡化存活時間(Progression Free Survival, PFS)」為主要療效指標的詴驗有 ... 證據顯示PFS 可以作為「整體存活(Overall Survival, OS」的替代性療效指標，且.

#3. 癌症臨床試驗的常用終點 - 呼吸希望

疾病無惡化存活期(Progression-free survival, PFS)：這是指從治療開始直至檢測到疾病惡化之間的時間。這通常用於研究不可能完全消除的晚期疾病 32 。疾病無惡化存活期定義為 ...

#4. Background - Progression-Free Survival - NCBI

Progression -free survival (PFS) is defined as the time from random assignment in a clinical trial to disease progression or death from any cause.

#5. Progression Free Survival - an overview | ScienceDirect Topics

Progression-Free Survival ... PFS is defined as the time from randomization to progression or death. (Time to progression is a related, less-preferred end point ...

#6. Progression-free survival at 24 months and subsequent ...

Progression -free survival (PFS) was defined as the time from the date of treatment to the first of either disease progression, relapse or ...

#7. The Value of Progression-Free Survival as a Treatment End ...

Putative surrogate end points, such as response rate and progression-free survival (PFS), are used based on the assumptions that shrinkage or ...

#8. Progression-Free Survival: Meaningful or Simply Measurable?

Some trials showing improvement in PFS, without a corresponding increase in overall survival (OS), have led to approval of new drugs and/or ...

#9. Patient Centered Approach: What Do Efficacy Endpoints Mean?

Progression Free Survival (PFS). – Overall Response Rate (ORR). – Disease Free Survival (DFS). – Time to Treatment Discontinuation (TTD) ...

#10. Systematic Review and Meta-Analysis of Correlation of ...

Background: Using progression-free survival (PFS)2, time from randomization to 2nd disease progression or death, is proposed as a surrogate ...

#11. Progression-free survival and time to progression as primary ...

We searched PubMed for randomized trials published between 2000 and 2007 in 10 leading medical journals. We abstracted data on progression-free survival (PFS), ...

#12. A Proposal for Progression-Free Survival Assessment in ...

Background/Aim: Progression-free survival (PFS), which is evaluated in oncology clinical trials, is determined based on tumor progression evaluated ...

#13. Progression Free Survival (PFS) After Cancer - Verywell Health

Progression -free survival (PFS) denotes the chances of staying free of disease progression for a group of individuals suffering from a ...

#14. Relationship between Progression-free Survival and Overall ...

Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology.

#15. Progression-Free Survival as a Surrogate ... - Value in Health

In a previous study, the quantitative relationship between progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM) was assessed.

#16. Exploration of modified progression-free survival as a novel ...

Background Progression-free survival (PFS) exhibits suboptimal performance as the surrogate endpoint for overall survival (OS) in trials studying immune ...

#17. Progression Free Survival (PFS), and ... - ASH Publications

CR and OS were co-primary endpoints. PFS was a secondary endpoint calculated from date of randomization to the earliest date of progression by ...

#18. Prediction of 5-year Progression-Free Survival in Advanced ...

Prediction of 5-year Progression-Free Survival in Advanced Nasopharyngeal Carcinoma with Pretreatment PET/CT using Multi-Modality Deep Learning- ...

#19. PFS-OS - NICE Decision Support Unit

Progression -free survival (PFS), time-to-progression (TTP) and overall survival (OS) are commonly used endpoints in randomised controlled trials (RCTs) and ...

#20. Progression-free survival: An important end point in evaluating ...

Progression status at 6 months is a strong predictor of survival, and 6moPFS is a valid end point for trials of therapy for recurrent malignant glioma. Earlier ...

#21. Progression-free survival (PFS) | Cancer.Net

Progression -free survival (PFS) ... The length of time during and after treatment that the cancer does not grow or spread further. This term is often used in the ...

#22. On-line Supplemental Appendix Protocol Definitions ...

Progression -free survival (PFS) was measured from the date of randomization to ... were used to assess tumor response and disease progression.

#23. Progression Free Survival - JMP

This process uses a modified survival plot and hazard ratio plot to compare the number and percentage of patients who have tumor progression or death, with ...

#24. Progression Free Survival Prediction for Head and Neck ...

Determining progression-free survival (PFS) for head and neck squamous cell carcinoma (HNSCC) patients is a challenging but pertinent task that ...

#25. What are Progression Free Survival (PFS) and Overall ...

HealthTree University, provided by the Myeloma Crowd, offers a comprehensive online multiple myeloma curriculum with lessons, quizzes and ...

#26. Starting point or endpoint in advanced HCC trial design?

The provocative part of this paper is the suggestion that progression-free survival (PFS) is an appropriate endpoint in trials of advanced ...

#27. Lack of Patient Understanding of PFS Points to Bigger Issues

Patients with cancer may not understand the meaning of progression-free survival (PFS), according to the results of a study recently ...

#28. Progression-free survival as a surrogate ... - Dove Medical Press

Background: The correlation between overall survival (OS) and progression-free survival (PFS) has been evaluated in patients with metastatic ...

#29. What do clinical trial results mean? | Cancer Research UK

Progression free survival (PFS), The time between treatment aimed at shrinking or controlling cancer, and signs that it has started to grow ...

#30. Long-term overall survival and progression-free survival in ...

Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch.

#31. Progression-free survival in the ICON8 trial – Authors' reply

However, we want to correct the authors with regards to the median progression free survival times, as the interval reported was the IQR, ...

#32. P2.01-049 Long Progression Free Survival and Overall ...

P2.01-049 Long Progression Free Survival and Overall Survival in Advanced NSCLC Patients with EGFR Mutation and Complete Response with TKI Treatment.

#33. Pembrolizumab Improves Progression-Free Survival vs ...

The investigators concluded: “Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line ...

#34. Cancers | Free Full-Text - MDPI

Progression -Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous ...

#35. Hepatic Progression-free and Overall Survival After Regional...

Objectives: Regional therapy for metastatic melanoma to the liver represents an alternative to systemic therapy. Hepatic progression-free survival (HPFS), ...

#36. AstraZeneca presents superior progression-free survival for ...

As the first Immuno-Oncology medicine to achieve improvement in progression-free survival in this setting, Imfinzi is showing clear potential to ...

#37. Response and progression-free survival according to planned ...

In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates ...

#38. Oropharynx Cancer Progression Free Survival Calculator

Predicted 2-year Progression Free Survival: Predicted 5-year Progression Free Survival:.

#39. Progression-Free Survival (PFS) | REVLIMID® (lenalidomide ...

Review the progression-free survival (PFS) observed with REVLIMID® + rituximab. Please see full Prescribing Information, including Boxed WARNINGS on fetal ...

#40. The Progression-Free Survival to Overall Survival Connection ...

If a therapy in castrate-resistant prostate cancer (CRPC) shows an improvement in progression-free survival, but not overall survival, ...

#41. Relationship Between Progression‐Free Survival, Objective ...

Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune ...

#42. Kaplan-Meier estimates of the probability of (A) progression ...

Download scientific diagram | Kaplan-Meier estimates of the probability of (A) progression-free survival (PFS) and (B) overall survival (OS), ...

#43. Progression-free Survival After MWA Plus Durvalumab and ...

Progression -free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (MIMIPAC) ...

#44. Clinical Trial Endpoints - OncologyPRO

Progression -Free Survival (PFS) is used commonly as a primary endpoint in phase III trials evaluating treatment of metastatic cancer. ◇. Since the size of a ...

#45. Clinical Significance of the Relationship between Progression ...

Progression -free survival (PFS) and OS are two common endpoints in cancer trials. OS is usually preferred, because it is reliable, precise, and meaningful, ...

#46. OS vs. PFS: What You Need to Know - Metastatic Trial Talk

Clinical trials are set up to look at specific outcomes. In some trials, researchers set out to look at progression-free survival (PFS), ...

#47. Progression-free survival (PFS) as a primary endpoint for ...

Progression -free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs). #158.

#48. Proven PFS benefit in 3L mCRC - Stivarga

For healthcare professionals only. Review the progression-free survival data for STIVARGA in MCC (metastatic colorectal carcinoma).

#49. A nomogram to predict the progression-free survival of clival ...

Chordoma has a poor prognosis because of a high recurrence rate. It has been reported that the 5-year rates for PFS and overall survival (OS) ...

#50. Extrapolation from Progression-Free Survival to Overall ...

This Research Paper reports on a literature review of trials using PFS as a surrogate for OS in oncology between 2012 and 2016; a workshop and interviews ...

#51. LYNPARZA® (olaparib) More Than Doubled Median ... - Merck

LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs ...

#52. challenges and methodologies in using progression free ...

If an alternative end point is sufficiently highly correlated with OS, it can be used as a surrogate. Progression-free survival (PFS) is the ...

#53. Immunotherapy doubles progression-free survival time of ...

'Progression-free survival' is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the ...

#54. The Value of Progression-Free Survival in Metastatic Breast ...

This study sought to estimate preferences for progression-free survival (PFS) relative to OS in metastatic breast cancer (mBC) among a ...

#55. Progression Free Survival Or Overall Survival Reconciling An ...

Building clinical trial designs that optimize across both progression free survival (PFS) and overall survival (OS) has historically proven.

#56. Updated Overall and Progression-Free Survival Data for ...

The mature data reveal a median progression-free survival (PFS) of 34.8 months with alectinib versus 10.9 months with crizotinib. The 5-year ...

#57. Consolidative Radiation Therapy Improves Progression-Free ...

... with diffuse large B-cell lymphoma, both bulky and nonbulky disease. ... Radiation Therapy Improves Progression-Free Survival in DLBCL.

#58. Correlation of progression free survival-2 and overall ... - X-MOL

Progression free survival (PFS) is a common primary endpoint, but, differential response to subsequent therapy may affect the correlation of PFS and OS.

#59. Progression-free survival as a surrogate endpoint in advanced ...

In phase III trials for neuroendocrine neoplasms (NENs), however, progression-free survival (PFS) is more frequently used, as NENs are relatively rare and ...

#60. ERLEADA - Second Progression-Free Survival (PFS2)

At the final analysis (following 428 events) for overall survival (OS), after a median follow-up of 52 months, the median PFS2 in the ERLEADA group was 55.6 ...

#61. Estimating progression-free survival in patients with ...

Overall survival was the interval from the date of histological diagnosis to date of death or last follow-up. Progression- free survival was the ...

#62. Progression-free survival is a suboptimal predictor for overall ...

Phase III metastatic trial utilization of progression-free (PFS) or overall survival (OS). •. PFS primary end-point (PEP) trials more likely to ...

#63. Are progression-free and disease-free survival the new gold ...

Overall survival is the gold standard and primary outcome of interest for cancer clinical trials. It is an 'appropriate measure' for evaluating ...

#64. Seeking Ways to Extend Progression-Free Survival ... - OncLive

At a median follow-up of 13.5 months, D-Rd reduced the risk of disease progression or death by 63% compared to patients in the control arm (Rd) ...

#65. Cancer Trials: Is Progression-Free Survival Enough?

A new study questions the use of progression-free survival as a surrogate endpoint in cancer clinical trials after finding it overlooks ...

#66. maintenance hormonal treatment improves progression free ...

The present study was conducted in patients with metastatic breast cancer. Its aim was to identify the factors which influence progression -free survival (PFS) ...

#67. Progression-Free Survival - Sirtex

In the intention-to-treat (ITT) population, the median Progression-Free Survival (PFS) was 4.1 months in the SIR-Spheres ® Y-90 resin microspheres arm vs.

#68. Progression-Free-Survival (PFS) Analysis in Solid Tumor ...

Progression -free survival (PFS) is commonly used as a primary endpoint in Phase III of solid tumor oncology clinical studies. PFS is defined as the time ...

#69. No link between progression-free survival, quality of life in ...

In clinical trials evaluating cancer interventions, there was no significant association between progression-free survival and ...

#70. The Significance of Progression-Free Survival as a Clinical ...

Here we discuss the relative merits of 2 survival end points-overall survival (OS) and progression-free survival (PFS)-and the value of PFS ...

#71. Primary end points of clinical trials - overall survival versus ...

This roundtable discussion looks at the advantages and disadvantages of overall survival and progression free survival as primary end points of clinical ...

#72. Progression-Free Survival and Patient Quality of Life Are Not ...

More evidence has been published to support the argument that a medication's ability to improve progression-free survival (PFS) says ...

#73. Progression-Free Survival Improved With All-Oral Ixazomib ...

Progression -Free Survival Improved With All-Oral Ixazomib Triplet in Newly-Diagnosed Transplant-Ineligible Myeloma. December 7, 2020.

#74. Appendix 1 to the guideline on the evaluation of anticancer ...

The use of progression-free survival (PFS) or disease-free survival (DFS) as endpoint in clinical efficacy trials presents several ...

#75. Ann Thorac Med

Progression -free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell ...

#76. The value of progression-free survival to patients with ...

Progression -free survival (PFS) is frequently used as a primary end point in oncology clinical trials. Employing PFS instead of overall survival as the ...

#77. Tag: progression-free survival - 2 Minute Medicine

#VisualAbstract Phase 3 trial shows adding clarithromycin to standard therapy does not improve progression-free survival in patients with multiple myeloma ...

#78. Is Disease-Free Survival a Meaningful Endpoint in NSCLC?

Adjuvant atezolizumab (Tecentriq) significantly improved disease-free survival compared with best supportive care after chemotherapy in ...

#79. Peripheral cytotoxic T lymphocyte predicts first-line ...

Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer. Xiao-Ran Liu.

#80. Progression-free survival is a robust surrogate endpoint of ...

Aim: We aimed to assess the surrogacy relationship of PFS with overall survival (OS) in clinical trials of systemic therapies targeting advanced ...

#81. New Horizons in the Treatment of Osteosarcoma | NEJM

At 2 years, the actuarial progression-free survival rate was 17% for patients in the observation group and 66% for those who received ...

#82. how pancreatic cancer disease burden can stymie enrolment ...

The trial result might show you have a drug that can offer a promising response rate, progression-free survival, and even sometimes overall ...

#83. Press Releases - Gilead Sciences

The five-year survival rate for this sub-type of breast cancer is 12%, ... The primary endpoint was progression-free survival (PFS, ...

#84. Figure 1 - View Image

Close. Figure 1: Progression-free survival and overall survival according to breast cancer subtype. (a) Progression-free survival for the same molecular ...

#85. New Trials in GI Cancers (Non-CRC) - Medscape

Primary outcomes are overall response rate (ORR) and progression-free survival (PFS). OS is a secondary outcome and QoL is not tracked.

#86. Bristol Myers Squibb's Opdivo posts another win in early lung ...

The latest event-free survival win adds to a previous success from the same ... stage II to IIIA NSCLC based on disease-free survival data.

#87. 図1-1 MACRO試験：Progression-free survival

図1-1 MACRO試験：Progression-free survival.

#88. HER2 Treatments See New Milestones in Colorectal Cancer ...

... showing that CRC patients with HER2 amplification detected by the Guardant360 assay had improved progression-free survival when treated ...

#89. HAI a Promising Option for Liver Cancer Patients - Clinical ...

... 13 (41%) were rendered disease-free in the liver. In the remaining 19 patients (59%), hepatic progression-free survival was 7.3 months.

#90. TG tumbles as FDA still hasn't found what its looking for in U2 ...

... of overall survival data from the phase 3 UNITY-CLL clinical trial. ... of progression-free survival and set TG up for an FDA filing.

#91. “Is progression-free survival time predictive of overall survival ...

The duration of progression-free survival (PFS) is the first criterion of judgment of more than 90% of the trials of the current innovative ...

#92. Jazz Pharmaceuticals Announces First Patient Enrolled in ...

... collaboration with F. Hoffmann-La Roche Ltd, will measure the progression-free survival and overall survival benefits of Zepzelca and Tece.

#93. Merck's KEYTRUDA® (pembrolizumab ... - Business Wire

... overall survival and progression-free survival when combined with ... disease progression on or after platinum-containing chemotherapy.

#94. EC grant Trodelvy marketing authorisation for treatment of ...

The five-year survival rate for this sub-type of breast cancer is 12%, ... endpoints of progression-free survival and overall survival.